Clinical Trial Detail

NCT ID NCT03170960
Title Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Exelixis
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

clear cell renal cell carcinoma

Therapies

Atezolizumab + Cabozantinib

Age Groups: adult senior

No variant requirements are available.